Table 5.
Overall survival rates categorized by HER2 status and adjuvant therapy.
| 3-year OS | 5-year OS | 6-year OS | 7-year OS | |
|---|---|---|---|---|
| HER2 positive | ||||
| Trastuzumab + CHT+ AHT | 97% | 96% | 96% | 96% |
| CHT + AHT | 98% | 98% | 92% | 92% |
| Trastuzumab + CHT | 95% | 92% | 92% | 86% |
| CHT | 82% | 65% | 65% | 65% |
| AHT | 91% | 83% | 79% | 79% |
| No adjuvant therapy | 75% | 63% | 55% | 55% |
| HER2 negative | ||||
| CHT + AHT | 98% | 95% | 93% | 92% |
| CHT | 89% | 86% | 83% | 83% |
| AHT | 95% | 90% | 88% | 88% |
| No adjuvant therapy | 81% | 75% | 73% | 64% |